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0bjeetive.v. The aim of this study ~BS tu BCICFS the hemorrhagic 
risk aswiated with fibrin-spedlir thrumbulytic therap! and iwt- 
sivo procedures with acute myncardia: inDrctinn. 
1Methodx. Five hundred seventy-five patients ww ewluetcd 
with six combined thrombolytic and catheteriratiun strategies. 
Palien@ were randomized to intravenous urokinee atone, recom- 
binant iissue-type plasmi~nogen aciivator (rt-P.4) slnrte, or hrrth; 
simuttanewrly they WPPI! randomized tu an immediate *enus d 
deferred catheterization strategy. Hemorrhagic ewnts were 8s. 
se&. The correlation of hemorrhage with clinical and hemu- 
static variabtes was ewtaoted. Prqecified lmnsfusion crileria 
were employed. 
Redfs. No diflerence in baseline characteristics w in hemor- 
rhagic complicatians ws noted nmung the three thromholytic 
Although intravenous thrombolytic therapy is the trcatmenr 
of choice for patients with acute myocardial infarctton. 
considerable controversy exists about the preferred pharma- 
cologic regimen as well as the timing ofcardix cathctcrir.t- 
gained, the possibility of reducing hemorrhagic complica- thrombolytic therapy. Vascular access was obtained by way 
tions has been raised. One objective ofthe Thrombolysis and of the right femoral artery without centrai <renaus puncture 
Angioplasty in Myocatdial infarction (TAMP 5 investigation unless angiuplasty was performed, the patient was hemody- 
was to examine the impact ofimmediate catheterization and namically compromised requiring right heart catheterization 
fibrin specificity on bleeding complications. or a temporary transvenous pacemaker was necessary. Only 
Fibrin-specific agents, such as recombinant tissue-type 5F or 6F Judkins catheters were used to perform angiogra- 
plasminogen activator @t-PA), were once heralded as being phy unless technical difficulty was encountered. In the case 
associated with less bleeding risk. However, clinical trials to of thrombolytic failure. rescue angioplasty was attetapted if 
date (1-3.7-10) have not proved this presumption correct. the vessel was considered suitable by the individual angiog- 
Agents that induce a more profound systemic fibrinolytic rapher. Thus, rescue angioplasty was attempted if Throm- 
state such as intravenous streptokinase, urokinase and anis- bolysis in Myocardial infarction (TIMI) flow grade 0 or I 
treplase have not been associated with a significant increase flow was present at the time of acae catnetenzattoo &d no 
in bleeding complications (2,l f-17). After completion of the contraindications existed to preclude such intetvention. If 
TAMI 2 study, it appeared that even combination therapy the vessel was patent (TIMI flow grade 2 to 31. no coronary 
with intravenous R-PA and urokinase was associated with a angioplasty was attempted unless clear evidence of ongoing 
similar degree of bleeding risk (IS). ischemia was present, 
The deferred cardiac catheterization strategy required 
Methods 
catheierization between day 5 and day IO after thrombolytic 
therapy. The patients were eligible to cross over to urgent 
Patient selection, The TAMI 5 trial was conducted a: catheterization if one of the following events occurred: 
seten individual cardiac referral centers in coltaboration I) symptoms compatible with m)ocardial ischemia lasting 
with 29 community hospitals (191. The protocol was ap- X!O mitt, despite standard nitrate therapy, with accompany- 
proved by the Institutional Review Board at all participating ing new ST segment or T wave changes od the electrocar- 
sites. diogram (ECG): 2) new hrpotension, pulmonary edema or 
Inc!usion and exclusion criteria have been previously holosystolic murmur: 3) new pump failure manifested by I h 
reported (19). Briefly, patients 218 yet ~76 years of age with of sustained hypotension with a systolic blood pressure 
an acute myocardial infarction of <6 h duration were en- ~90 mm Hg or requirement for inotropic support for I h 
rolled. Specific exclusion criteria related to hemorrhagic risk without an obvious noncardiac cause. 
included 1) history of any bleeding diathesis; 2) any gastro- In-haspital management. All patients were treated with 
intestinal or genitourinary bleeding within the previous 4 oral aspirin, 325 mglday, on entry into the trial. Intravenous 
weeks; 3) history of stroke or transient ischemic attack; administration of heparin was started (I ,000 U/h) at the end 
4) major surgery or organ biopsy within 14 days; 5) uncon- of infusion of the thromholytic agent and was maintained for 
trolled hypertension (blood pressure >18O/I 10 mm Hg) after 248 h with the dose adjusted to maintain the activated 
treatment for pain or coronary &hernia; 6) prolonged partial thromboplastin time between 1.5 and 2 times the 
(>I0 mitt) cardiopulmonary resuscitation; 7) severe trauma control value for our laboratory. In the aggressive strategy, 
within the previous 6 months. an additional 5,000 U of heparin was given when vascular 
Randomization and therapy. After informed consent was access was obtained in the catheterization laboratory and, if 
obtained, patients were randomly assigned to both a throm- rescue angioplasty was attempted, an additional 2,ooO to 
bolytic regimen and a cathetedzation strategy. The patients 5,ooO U/h was given if necessary. 
were randomized to receive either intravenous urokinase, Assessment of bleeding complkatiaas. Clinical research 
t-t-PA or a combination of the two agents. Simultaneously, nurses evaluated each uatient dailv for bleedina comolica- 
they were randomly assigned to either an aggressive (imme- tions. Occult bleeding’ftom gastrointestinal sourced was 
diate) cardiac catheterization strategy or a deferred proce- checked routinely. Hematologic variables obtained included 
dure performed before hospital discharge. nadir hematocrit, change from baseline to nadir hematocrit 
Urokinase (Abbokinase, Abbott Laboratories) was given (Ahemalocrit), number of packed red blood cells transfused, 
as a IS-million U intravenous holus followed by a I.5 baseline fibrinogen, nadir hbrhtogen (@liter) and peak Rbrht 
million U infusion over 60 min. Treatment with rt-PA was and fibrinogen degradation product t&ml) levels. Also, a 
given as 60 mg in the 1st h, with an initial Cmg bolus dose, bleeding index as defined by Landefeld et al. (20) (Ahema- 
and a ZO-mg infusion each hour for the next 2 h for a total tocritl3 + packed red blood cells transfused (UN was deter- 
dose of 100 mg intravenously. Combination therapy con- mined for each patient. 
sisted of I.5million U of intravenous urokinase over 60 min Clinical bleeding events were recorded on case report 
with a l-mglkg dose of II-PA (kO% given as a bohts) with a forms and independently reviewed by monitors unaware of 
maximal dose of W mg over 69 min. the paIient’s randomization assignment. After hospital dis- 
The aggressive catheterization strategy entailed an imme- charge. all charts were again reviewed for any previously 
diate angiogram of the infarct-reiated vessel as close as unrecorded bleeding episodes. Individual patient blood loss 
possible to but not before 90 min after the initiation of was defined as follows: minor if it was of no clinical 
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consequence, did 1101 require a transfusion and tolal blood 
loss was ~250 ml: rnodprare if 250 to 500 ml of observed 
blood loss was noted: .revere if there was >SW ml of blood 
toss necessitating a fransfusion: or l~e-dwuv~Gng if there 
was intracranial, gastrointestinal or other internal or external 
bleeding causing hypozension and neccssilaling an emer- 
gency transfusion. intracranial hemorrhage was recorded 
when any new neurologic event wi?s noted and was docu- 
mented by cranial tomography. Suspected retroperttoneal 
bleeding was documented by a computed tomographic scan 
of the abdomen. 
On the basis of pretrial investigator consensus. a goal was 
established to restrict transfusion of blood cells to patients 
with a hematocrit of 522% as long as hemodynamic stability 
was maintained. In the setting of hemodynamic instability, 
unresponsive to crystalloid infusion and with clinical evi- 
dence of sign&ant blood loss, transf&w was allowed 
regardless of measured hematacrit. This posture represented 
a change from previous studies where no threshold hemato- 
crit value for transfusion was defined. 
Blood samples were collected on 0.01 mmoUliter citrate 
and 200 kIU& aprolinin at baseline, 4 h and 24 b afler 
initiation of thmmbolytic therapy and were immediately 
processed and kept Frozen at -20°C until assayed by the 
coagulation laboratory. Fibrinogen was determined by the 
modified coagulation rate assay of Claws. Fibrin and fibrin- 
ogen degradation products were analyzed by the tanned red 
cell agglutination inhibition technique at the core hematol- 
ogy laboratory at the University of Vermont. These tech- 
niques have previously been described (21). 
StaWcal met&Is. Statistical analysis was performed a~ 
the TAMI Coordinating Center at Duke University Medical 
Center. For descriptive presentation of the data. continuous 
baseline and outcome variables were summarized by using 
the median and inrerquartile range, while discrete variables 
were described in tennsofpercentages. Twcway analysisof 
variance was used to w&mine the effect of drug treatment. 
catheterization strategy and possible interactions ‘cctween 
drug treatment and catheterization strategy on bleeding and 
coagulation variables. Pearson correlation coefficienls were 
used to determine the magnitude of the relations between 
bleeding measures and coagulation variables. AN analyses 
wex xnmined according to the principle of intention to 
treat. A safe:? and data monitoring board met after 200 and 
4W patients had teen enrolled in the study. l?e board 
remained wirhout knowledge of treatment groups and exam- 
ined the data specifically for safety issues only. 
Refiult!3 
Baseline chwaclerislics. Baseline clinical characlerislics 
for all treatment strategies are presented in Table I. There 
was no d8erence in baseline characteristics among patients 
assigned IO the three thrombolytic treatment groups. How- 
ever, patients ztssigned to immediate catheterization experi- 
enced more anterior infarctian. 
Hemorrhagic mmplications. Quanritative measurements 
reflecting bIood loss for nonsurgical patients are displayed in 
Table 2. There was no significant difference in hemorrhagic 
events regardless of thmmbolytic strategy. Patients who 
underwent agqessive cardiac catheterization showed a sig- 
nificantly greater change in hematocrit (p = 0.0025) as well 
as a higher bleeding index (p = 0.024). The difference in 
nadir hematocrit between the immediate and deferred catb- 
eterization strategies approached statistical significance (p = 
either study had a related fatal bleeding complication. In the hemorrhagic risk will depend more on bedside assessment 
present study, only one patient had a life-threatening bleed- than on laboratory markers. The most likely explanation for 
ing event. With careful attention to technique and postpro- our lindings, however, is that all fibrinolytic agents fail to 
cedural monitoring, major bleeding is a rare event. differentiate physiologic hemostatic plugs from a localized 
Though minor bleeding was more common in patients coronary thrombosis (26). 
who underwent immediate catheterization, there was no Transfwion requirements. The observation that transfu- 
significant clinical difference between bleeding rates in this sion rate is only minimally increased with immediate cnthe- 
group and in those assigned to the deferred strategy. Though terization is important. Historically, medical teaching has 
a statistically significant difference was noted (as measured defined an optimal hematocrit in critically ill patients to be 
by change in hematocrit and bIeeding index in nonsurgical ~32% (271. However, the data supporting this level has 
patients undergoing immediate catheterization), only a mi- come from postoperative patients with comorbid medical 
nor increase in transfusion requirements was seen. These illnesses. In the present study a well defined transfusion 
findings held true for all three drug strategies. threshold was employed to avoid the excess use of blood 
Clinical role of fibrin specificity. The observation that oroducts. As a consenuence. onlv 10% of nonsuraical na- . . I . 
rt-PA offers no advantase in reducine bleedioc! comdicadons 
is not surprising. As p&viously documented in the studies 
iients required two or more units of packed red cells com- 
pared with =20% of patients in the TIM1 I and TAM1 1 
comparing r&PA and streptokinase (2.3). no significant dif- studies (3,9). These findings suggest that blood product 
ference in bleeding rates has been observed. Furthermore, usage can he substantially reduced if lower transfusion 
there has been no difference in the requirement for blood criteria are employed. 
transfusions in these patients. 
Previous studies (3,8,10,23) hzti& found only a weak 
correlation between hemostatic variables and bleeding risk. 
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